211 related articles for article (PubMed ID: 9304127)
1. [Deoxypyridinoline and other biochemical markers of bone resorption in distinct pathologies].
Rivero Marcotegui A; Palacios Sarrasqueta M; Grijalba Uche A; Martínez Rodríguez JL; Sorbet Zubiría MJ; García Merlo S
Rev Clin Esp; 1997 Jun; 197(6):389-92. PubMed ID: 9304127
[TBL] [Abstract][Full Text] [Related]
2. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
3. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.
Robins SP; Woitge H; Hesley R; Ju J; Seyedin S; Seibel MJ
J Bone Miner Res; 1994 Oct; 9(10):1643-9. PubMed ID: 7817812
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness of bone remodelling biochemical markers in the diagnosis and follow-up of Paget's bone disease, primary hyperparathyroidism, tumor hypercalcemia, and postmenopausal osteoporosis. II. Bone resorption markers].
de la Piedra Gordo C; Torres Jiménez R
An Med Interna; 1990 Oct; 7(10):534-8. PubMed ID: 2104101
[TBL] [Abstract][Full Text] [Related]
5. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
6. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
7. Changes in markers of bone formation and resorption in a bed rest model of weightlessness.
Lueken SA; Arnaud SB; Taylor AK; Baylink DJ
J Bone Miner Res; 1993 Dec; 8(12):1433-8. PubMed ID: 8304043
[TBL] [Abstract][Full Text] [Related]
8. [Bone resorption markers].
Takahashi M; Inoue T
Rinsho Byori; 1996 May; 44(5):415-22. PubMed ID: 8676559
[TBL] [Abstract][Full Text] [Related]
9. Biochemical markers of bone turnover.
Rosalki SB
Int J Clin Pract; 1998 Jun; 52(4):255-6. PubMed ID: 9744151
[TBL] [Abstract][Full Text] [Related]
10. [Use of biochemical markers of bone turnover in Paget's disease of bone].
Vignot E; Meunier PJ
Ann Biol Clin (Paris); 2001; 59(3):309-11. PubMed ID: 11397680
[No Abstract] [Full Text] [Related]
11. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
12. Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis.
Majkić-Singh N; Ilić M; Ignjatović S; Aleksandra-Postić-Grujin
Clin Lab; 2002; 48(7-8):407-13. PubMed ID: 12146575
[TBL] [Abstract][Full Text] [Related]
13. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
14. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
15. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
Torres R; de la Piedra C; Rapado A
Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049
[TBL] [Abstract][Full Text] [Related]
16. [The usefulness of biochemical markers of bone remodelling in the diagnosis and follow-up of Paget's disease of bone, primary hyperparathyroidism, tumoral hypercalcemia and postmenopausal osteoporosis. I. The markers of bone formation].
de la Piedra Gordo C; Torres Jiménez R
An Med Interna; 1990 Sep; 7(9):480-6. PubMed ID: 2103291
[TBL] [Abstract][Full Text] [Related]
17. The urinary excretion of inorganic pyrophosphate in hyperparathyroidism, hyperthyroidism, Paget's disease and other disorders of bone metabolism.
Russell RG; Hodgkinson A
Clin Sci; 1969 Jun; 36(3):435-43. PubMed ID: 4307562
[No Abstract] [Full Text] [Related]
18. Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview.
Simsek B; Karacaer O; Karaca I
Chin Med J (Engl); 2004 Feb; 117(2):291-5. PubMed ID: 14975218
[TBL] [Abstract][Full Text] [Related]
19. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
20. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
Hamdy NA; Papapoulos SE; Colwell A; Eastell R; Russell RG
Bone Miner; 1993 Jul; 22(1):1-8. PubMed ID: 8219934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
